Drugs / D5W

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT07568470 Apr → Sep 2026 expected US Neuropathy Centers Enrolling by invitation No outcome recorded
Also used as a comparator or background therapy in 5 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00460499 Comparator Jul 2004 → Mar 2015 glucose metabolism disease American Heart Association Completed No outcome recorded
Phase 31 trial
Phase 3 NCT06030609 Comparator Sep 2024 → Feb 2026 disorder of acid-base balance King Chulalongkorn Memorial Hospital Completed No outcome recorded
Phase 42 trials
Phase 4 NCT06308887 Comparator Oct 2023 → Feb 2024 chronic pain syndrome, osteoarthritis, knee Kastamonu University Completed No outcome recorded
Phase 4 NCT05220527 Comparator Aug 2020 → Jul 2022 osteoarthritis, knee Taipei Medical University Unknown No outcome recorded
Phase not applicable1 trial
NCT04579783 Comparator Nov 2020 → Oct 2022 carpal tunnel syndrome National Taiwan University Hospital Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as D5W “These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl” NCT00460499
2

“Ringer lactate solution (RLS) and normal saline solution (NSS) with dextrose water (D5W)” NCT06030609

NCT07568470

Known as 5% Dextrose in Water “non-guided subcutaneous infiltration of D5W (5% Dextrose in Water)” NCT07568470
Known as Dextrose 5% in water ClinicalTrials.gov intervention name — accepted as the source's own label NCT06308887
1

NCT04579783

Known as dextrose water “Ringer lactate solution (RLS) and normal saline solution (NSS) with dextrose water (D5W)” NCT06030609
Known as vitagen ClinicalTrials.gov intervention name — accepted as the source's own label NCT05220527
Route Intravenous “D5W+80unitsInsulin+40mEqKCL IV” NCT00460499